Zobrazeno 71 - 80
of 387
pro vyhledávání: '"Michael S. Lawrence"'
The apolipoprotein B mRNA editing enzyme catalytic polypeptide-like APOBEC3A and APOBEC3B have emerged as key mutation drivers in cancer. Here, we show that APOBEC3A and APOBEC3B activities impose a unique type of replication stress by inducing abasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c77bc1454ad4360aa6e0de531aaf6cc
https://doi.org/10.1158/0008-5472.c.6508869
https://doi.org/10.1158/0008-5472.c.6508869
Autor:
Peter S. Hammerman, Kevin P. White, Everett E. Vokes, Ezra E.W. Cohen, Mark W. Lingen, Kerstin Stenson, Elizabeth Blair, Louis Portugal, Alexander Langerman, Ralph R. Weichselbaum, Rebecca DeBoer, Johannes Brägelmann, Gad Getz, Michael S. Lawrence, Juok Cho, Petar Stojanov, Trevor J. Pugh, Christopher Brown, Thomas Stricker, Chandra S. Pedamallu, Arun Khattri, Michaela K. Keck, Zhixiang Zuo, Tanguy Y. Seiwert
Purpose: The genetic differences between human papilloma virus (HPV)–positive and –negative head and neck squamous cell carcinomas (HNSCC) remain largely unknown. To identify differential biology and novel therapeutic targets for both entities, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887e88f5dff6ee320e843dfb112bf9ca
https://doi.org/10.1158/1078-0432.c.6522954
https://doi.org/10.1158/1078-0432.c.6522954
This file contains the data showing expression of APOBEC3A/B in cancer cell lines and activity of APOPBEC3A/B in cancer cell lines. It is linked to the main figure 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5073592090f7a2cb2a27b7b250527bf2
https://doi.org/10.1158/0008-5472.22414032
https://doi.org/10.1158/0008-5472.22414032
Autor:
Aaron N. Hata, Alice T. Shaw, Justin F. Gainor, Michael S. Lawrence, Christopher G. Azzoli, Cyril H. Benes, Rebecca J. Nagy, Ashish Saxena, Subba R. Digumarthy, Sara E. Stevens, Hetal D. Marble, Andrew Do, Emily Chin, Beow Y. Yeap, Nathaniel A. Adams, Audris Oh, Kylie Prutisto-Chang, Marguerite M. Rooney, Jessica J. Lin, Adam Langenbucher, Jochen K. Lennerz, Satoshi Yoda, Ibiayi Dagogo-Jack
supplementary tables, figure legends, methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1649086b237d5a20a9e4d0682c77ba05
https://doi.org/10.1158/1078-0432.22478537.v1
https://doi.org/10.1158/1078-0432.22478537.v1
Autor:
Justin F. Gainor, Alexander Drilon, Aaron N. Hata, Sai-Hong Ignatius Ou, Michael S. Lawrence, Alice T. Shaw, Jochen K. Lennerz, Beow Y. Yeap, Lecia V. Sequist, Jennifer S. Temel, Christina J. Falcon, Adam J. Schoenfeld, Adam Langenbucher, Harper G. Hubbeling, Wafa Malik, Kylie Prutisto-Chang, Jennifer Peterson, Andrew Do, Charlotte Lee, Subba R. Digumarthy, Ibiayi Dagogo-Jack, Ramin Sakhtemani, Ted W. Johnson, Viola W. Zhu, Satoshi Yoda, Noura J. Choudhury, Jessica J. Lin
Purpose:Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5172c89aba121b65d81b64c96d23e465
https://doi.org/10.1158/1078-0432.c.6530057.v1
https://doi.org/10.1158/1078-0432.c.6530057.v1
Autor:
Aaron N. Hata, Alice T. Shaw, Justin F. Gainor, Michael S. Lawrence, Christopher G. Azzoli, Cyril H. Benes, Rebecca J. Nagy, Ashish Saxena, Subba R. Digumarthy, Sara E. Stevens, Hetal D. Marble, Andrew Do, Emily Chin, Beow Y. Yeap, Nathaniel A. Adams, Audris Oh, Kylie Prutisto-Chang, Marguerite M. Rooney, Jessica J. Lin, Adam Langenbucher, Jochen K. Lennerz, Satoshi Yoda, Ibiayi Dagogo-Jack
Purpose:Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d4a11d90d4d7d85f54075c6b3853692
https://doi.org/10.1158/1078-0432.c.6529973.v1
https://doi.org/10.1158/1078-0432.c.6529973.v1
Autor:
Ramin Sakhtemani, Madusha L W Perera, Daniel Hübschmann, Reiner Siebert, Michael S Lawrence, Ashok S Bhagwat
Publikováno v:
Nucleic Acids Research. 50:5145-5157
Activation-induced deaminase (AID) is a DNA-cytosine deaminase that mediates maturation of antibodies through somatic hypermutation and class-switch recombination. While it causes mutations in immunoglobulin heavy and light chain genes and strand bre
Publikováno v:
STAR protocols. 4(1)
Computational pipelines for chromatin immunoprecipitation sequencing analysis can neglect colocalization events that occur in a mere subset of the genome. Here, we detail a streamlined approach for assessing colocalization of chromatin-bound proteins
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Baoyan Bai, Jillian F. Wise, Daniel Vodák, Sigve Nakken, Ankush Sharma, Yngvild Nuvin Blaker, Marianne Brodtkorb, Vera Hilden, Gunhild Trøen, Weicheng Ren, Suzanne Lorenz, Michael S. Lawrence, Ola Myklebost, Eva Kimby, Qiang Pan-Hammarstrom, Leonardo Meza-Zepeda, Klaus Beiske, Erlend B. Smeland, Eivind Hovig, Ole Christian Lingjærde, Harald Holte, June Helen Myklebust
Publikováno v:
Blood. 140:6411-6412